IFN-zeta/ limitin: a member of type I IFN with mild lympho-myelosuppression
- PMID: 15963247
- PMCID: PMC6740103
- DOI: 10.1111/j.1582-4934.2005.tb00353.x
IFN-zeta/ limitin: a member of type I IFN with mild lympho-myelosuppression
Abstract
Interferon (IFN)-Zeta/limitin has been considered as a novel type I IFN by the Nomenclature Committee of the International Society for Interferon and Cytokine Research. IFN-Zeta/limitin shows some sequence homology with IFN-alpha and IFN-beta, has a globular structure with five alpha-helices and four loops, and recognizes IFN-alpha/beta receptor. Although IFN-zeta/limitin displays antiviral, immunomodulatory, and antitumor effects, it has much less lympho-myelosuppressive activities than IFN-alpha. Treatment of cells with type I IFNs induces and/or activates a number of molecules, which regulate cell cycle and apoptosis. It is noteworthy that IFN-zeta/limitin activates the Tyk2-Daxx and Tyk2-Crk pathways weaker than IFN-alpha. Because experiments using antisense oligonucleotides have revealed their essential role in type I IFN-related suppression of lympho-hematopoiesis, little ability of IFN-zeta/limitin to activate the Tyk2-dependent signaling pathway may explain its uniquely narrow range of biological activities. Further analysis of structure-function relationship of type I IFNs will establish an engineered cytokine with useful features of IFN-zeta/limitin.
Similar articles
-
Differential effects of a novel IFN-zeta/limitin and IFN-alpha on signals for Daxx induction and Crk phosphorylation that couple with growth control of megakaryocytes.Exp Hematol. 2005 Apr;33(4):495-503. doi: 10.1016/j.exphem.2005.01.002. Exp Hematol. 2005. PMID: 15781341
-
Interferon-zeta/limitin: novel type I interferon that displays a narrow range of biological activity.Int J Hematol. 2004 Nov;80(4):325-31. doi: 10.1532/ijh97.04087. Int J Hematol. 2004. PMID: 15615256 Review.
-
Limitin: an interferon-like cytokine without myeloerythroid suppressive properties.J Mol Med (Berl). 2001 May;79(4):168-74. doi: 10.1007/s001090100206. J Mol Med (Berl). 2001. PMID: 11409707 Review.
-
Limitin, an interferon-like cytokine, transduces inhibitory signals on B-cell growth through activation of Tyk2, but not Stat1, followed by induction and nuclear translocation of Daxx.Exp Hematol. 2003 Dec;31(12):1317-22. doi: 10.1016/j.exphem.2003.08.011. Exp Hematol. 2003. PMID: 14662340
-
A new interferon, limitin, displays equivalent immunomodulatory and antitumor activities without myelosuppressive properties as compared with interferon-alpha.Exp Hematol. 2004 Sep;32(9):797-805. doi: 10.1016/j.exphem.2004.06.008. Exp Hematol. 2004. PMID: 15345280
Cited by
-
Intricacies of cardiac damage in coxsackievirus B3 infection: implications for therapy.Int J Cardiol. 2014 Dec 15;177(2):330-339. doi: 10.1016/j.ijcard.2014.09.136. Epub 2014 Oct 18. Int J Cardiol. 2014. PMID: 25449464 Free PMC article. Review.
-
Expression and mechanisms of interferon-stimulated genes in viral infection of the central nervous system (CNS) and neurological diseases.Front Immunol. 2022 Oct 17;13:1008072. doi: 10.3389/fimmu.2022.1008072. eCollection 2022. Front Immunol. 2022. PMID: 36325336 Free PMC article. Review.
-
Structural analysis of cytokines comprising the IL-10 family.Cytokine Growth Factor Rev. 2010 Oct;21(5):325-30. doi: 10.1016/j.cytogfr.2010.08.003. Epub 2010 Sep 16. Cytokine Growth Factor Rev. 2010. PMID: 20846897 Free PMC article. Review.
-
Antitumour actions of interferons: implications for cancer therapy.Nat Rev Cancer. 2016 Mar;16(3):131-44. doi: 10.1038/nrc.2016.14. Nat Rev Cancer. 2016. PMID: 26911188 Review.
-
Modulation of interferon activity-associated soluble molecules by appendicitis and appendectomy limits colitis-identification of novel anti-colitic targets.J Interferon Cytokine Res. 2015 Feb;35(2):108-15. doi: 10.1089/jir.2014.0091. Epub 2014 Sep 22. J Interferon Cytokine Res. 2015. PMID: 25243802 Free PMC article.
References
-
- Oritani K, Medina KL, Tomiyama Y, Ishikawa J., Okajima Y, Ogawa M, Yokota T, Aoyama K, Takahashi I, Kincade PW, Matsuzawa Y. Limitin: An interferon‐like cytokine that preferentially influences B‐lymphocyte precursors. Nat Med. 2000; 6: 659–66. - PubMed
-
- Kawamoto S, Oritani K, Asada H, Takahashi I, Ishikawa J, Yoshida H, Yamada M, Ishida N, Ujiie H, Masaie H, Tomiyama Y, Matsuzawa Y. Antiviral activity of limitin against encephalomyocarditis virus, herpes simplex virus, and mouse hepatitis virus: diverse requirements by limitin and alpha interferon for interferon regulatory factor 1. J Virol. 2003; 77: 9622–31. - PMC - PubMed
-
- Oritani K, Tomiyama Y. Interferon‐limitin: novel type I interferon that displays a narrow range of biological activity. Int J Hematol. 2004; 80: 325–31. - PubMed
-
- Oritani K, Hirota S, Nakagawa T, Takahashi I, Kawamoto S, Yamada M, Ishida N, Kadoya T, Tomiyama Y, Kincade PW, Matsuzawa Y. T lymphocytes constitutively produce an interferonlike cytokine limitin characterized as a heat‐ and acid‐stable and heparin‐ binding glycoprotein. Blood 2003; 101: 178–85. - PubMed
-
- Oritani K, Kincade PW, Zhang C, Tomiyama Y, Matsuzawa Y. Type I interferons and limitin: a comparison of structures, receptors, and functions. Cytokine Growth Factor Rev. 2001; 12: 337–48. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
